NICE has launched a consultation on the review of their methods for health technology evaluation.
The consultation will cover methods for the evaluation of medicines, medical technologies and diagnostics, and will apply to all four of NICE’s health technology evaluation programmes. The principal aims of the review are to support faster access to clinically and cost-effective health technologies, and to encourage companies to launch their products first in the UK. The review also places a focus on ensuring that methods are flexible and adaptable in order to help deal with innovative technologies efficiently.
The proposals for change include the removal of the End of Life (EoL) modifier for QALY value, and the addition of a modifier for disease severity.
Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, said:
“These are exciting times, where innovation in science and technology are of great interest to many in our country. As we develop a new regulatory and access environment for medicines, medical devices, diagnostics and digital health technologies, our methods should be aimed at supporting early patient access at a reasonable cost to the NHS.”
“Ensuring that our methods are clear, transparent and predictable should allow us to speed up evaluation processes for new and emerging technologies. This is particularly important in our response to COVID-19, but also
allows us to further consider how to best evaluate the value of specific new technologies such as cell and gene therapies.”
The consultation is now open and closes on 18 December 2020. It is an opportunity to provide your thoughts on NICE’s proposals and how they’ve taken evidence and considerations into account, as well as any potential implications.
MAP will take the thoughts of its members into account in its response to the consultation.
For access to the consultation document and further information on how to take part, see the consultation page on the NICE website.